Loading
Harmony Biosciences Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Marshman Fund Trust II, was filed 16 Oct 2020.
Insider Decl.
321
Thresholds
n/a
Buy Volume
€11M
8 ops. · all time
Sell Volume
€392M
185 ops. · all time
Who traded when
BuySaleDierks Jeffrey9 sales
Kapadia Sandip9 sales
Kumar Budur7 sales
Dayno Jeffrey M.3 sales
Valor IV Pharma Holdings, LLC2 sales
Marshman Fund Trust II1 sale
Since the insiders bought
- -2.5%Entry US$38.99 · Close at T+365 US$38.03
- +5.3%Entry US$35.20 · Close at T+365 US$37.07
- +1.2%Entry US$34.00 · Close at T+365 US$34.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Harmony Biosciences Holdings, Inc. Buy (bullish), based on 12 analysts. Average price target: US$48.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,247 of 26,248 companies
79.2
score / 100
Value74
Quality84
FCF yld15%
Earn yld7.0%
EV/EBITDA9.5x
ROE20%
Gross mgn77%
Net mgn18%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$38.70
Analyst consensus
12 analystsBuy
US$30.00Target US$48.25(+25%)US$70.00
Income statement
RevenueUS$868.5M
Gross profitUS$670.1M77% margin
EBITDAUS$255M29% margin
Net incomeUS$158.7M18.9% margin
Valuation
PER (trailing)12.5x
PER (forward)5.5x
P/Book2.3x
Beta1.01
Balance sheet & cash
Market capUS$2.3B
Total debtUS$163.7M
Free Cash FlowUS$347.9M
Debt / Equity16%
Profitability & ownership
ROE20.5%
ROA11.6%
% insiders1.2%
% institutions99.7%
Last declaration on 18 September 2026
Declarations321 total
35,852 shares@ US$42.740.068% mcap50.1% of flowCommonSEC144:0001950047-26-009670
25,446 shares@ US$30.270.034% mcap15.6% of flowCommon StockSEC:0002009762-26-000006:7
900 shares@ US$30.690.0012% mcap0.6% of flowCommon StockSEC:0002009762-26-000006:0
900 shares@ US$30.270.0012% mcap0.5% of flowCommon StockSEC:0002009762-26-000006:1
1,800 shares@ US$43.01460.0034% mcap1.6% of flowCommon StockSEC:0002009762-26-000006:2
400 shares@ US$30.690.0005% mcap0.2% of flowCommon StockSEC:0002009762-26-000006:3
400 shares@ US$30.270.0005% mcap0.2% of flowCommon StockSEC:0002009762-26-000006:4
800 shares@ US$43.000.0015% mcap0.7% of flowCommon StockSEC:0002009762-26-000006:5
10,406 shares@ US$30.690.014% mcap6.5% of flowCommon StockSEC:0002009762-26-000006:6
35,852 shares@ US$43.05450.068% mcap31.2% of flowCommon StockSEC:0002009762-26-000006:8
800 shares@ US$42.210.0015% mcap1.1% of flowCommonSEC144:0001950047-26-009641
1,800 shares@ US$42.170.0033% mcap2.5% of flowCommonSEC144:0001950047-26-009579
5,500 shares@ US$41.98390.0099% mcap4.3% of flowCommon StockSEC:0002009762-26-000005:0
4,500 shares@ US$42.24750.0081% mcap3.5% of flowCommon StockSEC:0002009762-26-000005:1
1,000 shares@ US$42.79470.0018% mcap0.8% of flowCommon StockSEC:0002009762-26-000005:2
12,200 shares@ US$30.690.016% mcap6.9% of flowCommon StockSEC:0002009762-26-000005:3
10,754 shares@ US$30.270.014% mcap6.0% of flowCommon StockSEC:0002009762-26-000005:4
22,954 shares@ US$43.10140.042% mcap18.2% of flowCommon StockSEC:0002009762-26-000005:5
28,454 shares@ US$42.250.052% mcap38.8% of flowCommonSEC144:0001950047-26-009207
5,500 shares@ US$41.86100.0% of flowCommonSEC144:0001950047-26-009141
700,883 shares@ US$37.901.11% mcap100.0% of flowCommonSEC144:0001950047-26-007827
25,000 shares@ US$36.96030.039% mcap16.1% of flowCommonSEC144:0001950047-26-006806
50,000 shares@ US$36.07650.076% mcap31.5% of flowCommonSEC144:0001950047-26-006634
45,594 shares@ US$35.2420.076% mcap28.2% of flowCommonSEC144:0001950047-26-006529
4,406 shares@ US$35.02090.0073% mcap2.7% of flowCommonSEC144:0001950047-26-006445
25 of 321 declarations
About Harmony Biosciences Holdings, Inc.
Valor IV Pharma Holdings, LLC sold EUR 111,343,514 on November 1, 2024 at Harmony Biosciences Holdings, Inc., then EUR 16,720,071 on November 5, 2024 as 10% Owner: these are the two largest sales in the record. Andreas Wicki (Director) sold EUR 25,725,839 on August 8, 2022. The 185 sales total EUR 392.3 million, with a median of EUR 417,499.
The 8 purchases date from the start of the record: on August 21, 2020, Marshman Fund Trust II (10% Owner) bought EUR 6,861,760, Novo Holdings A/S (10% Owner) EUR 2,678,256 and Jack Nielsen (Director) EUR 501,520. From August 20, 2020 to August 26, 2020, 3 filers bought EUR 10,559,604, which is all of the purchases. They make up 4% of open-market trades.
Read moreShow less
Jack Nielsen is also the most frequent filer, with 74 filings, 68 of them sales and 6 purchases; Jeffrey Dierks (CHIEF COMMERCIAL OFFICER) signs 68 and Jeffrey M. Dayno (PRESIDENT, CEO) 31. Of 320 filings since August 24, 2020, 139 fall in 2022, 46 in 2025 and 48 in 2026. There are 81 option exercises and 21 grants. The US healthcare and pharma company is worth USD 2.25 billion. Last twelve months: 54 filings, 13 sales, no purchase.
